Highlighted Publications

Other Publications

Saxena, M., Anker, J. F., Kodysh, J., O'Donnell, T., Kaminska, A. M., Meseck, M., Hapanowicz, O., Niglio, S. A., Salazar, A. M., Shah, H. R., Kinoshita, Y., Brody, R., Rubinsteyn, A., Sebra, R. P., Bhardwaj, N., & Galsky, M. D. (2025). Atezolizumab plus personalized neoantigen vaccination in urothelial cancer: a phase 1 trial. Nature cancer, 10.1038/s43018-025-00966-7.

Saxena, M., Marron, T. U., Kodysh, J., Finnigan, J. P., Jr, Onkar, S., Kaminska, A., Tuballes, K., Guo, R., Sabado, R. L., Meseck, M., O'Donnell, T. J., Sebra, R. P., Parekh, S., Galsky, M. D., Blasquez, A., Gimenez, G., Bicak, M., Cimen Bozkus, C., Delbeau-Zagelbaum, D., Rodriguez, D., … Bhardwaj, N. (2025). PGV001, a Multi-Peptide Personalized Neoantigen Vaccine Platform: Phase I Study in Patients with Solid and Hematologic Malignancies in the Adjuvant Setting. Cancer discovery, 15(5), 930–947.

Patskovsky, Y., Natarajan, A., Patskovska, L., Nyovanie, S., Joshi, B., Morin, B., Brittsan, C., Huber, O., Gordon, S., Michelet, X., Schmitzberger, F., Stein, R. B., Findeis, M. A., Hurwitz, A., Van Dijk, M., Chantzoura, E., Yague, A. S., Pollack Smith, D., Buell, J. S., Underwood, D., … Krogsgaard, M. (2023). Molecular mechanism of phosphopeptide neoantigen immunogenicity. Nature communications, 14(1), 3763.

Gigoux, M., Holmström, M. O., Zappasodi, R., Park, J. J., Pourpe, S., Bozkus, C. C., Mangarin, L. M. B., Redmond, D., Verma, S., Schad, S., George, M. M., Venkatesh, D., Ghosh, A., Hoyos, D., Molvi, Z., Kamaz, B., Marneth, A. E., Duke, W., Leventhal, M. J., Jan, M., … Merghoub, T. (2022). Calreticulin mutant myeloproliferative neoplasms induce MHC-I skewing, which can be overcome by an optimized peptide cancer vaccine. Science translational medicine, 14(649), eaba4380.

Salomé, B., Sfakianos, J. P., Ranti, D., Daza, J., Bieber, C., Charap, A., Hammer, C., Banchereau, R., Farkas, A. M., Ruan, D. F., Izadmehr, S., Geanon, D., Kelly, G., de Real, R. M., Lee, B., Beaumont, K. G., Shroff, S., Wang, Y. A., Wang, Y. C., Thin, T. H., … Horowitz, A. (2022). NKG2A and HLA-E define an alternative immune checkpoint axis in bladder cancer. Cancer cell, 40(9), 1027–1043.e9.

Cimen Bozkus, C., Blazquez, A. B., Enokida, T., & Bhardwaj, N. (2021). A T-cell-based immunogenicity protocol for evaluating human antigen-specific responses. STAR protocols, 2(3), 100758.

Hobbs, G., Cimen Bozkus, C., Moshier, E., Dougherty, M., Bar-Natan, M., Sandy, L., Johnson, K., Foster, J. E., Som, T., Macrae, M., Marble, H., Salama, M., El Jamal, S. M., Zubizarreta, N., Wadleigh, M., Stone, R., Bhardwaj, N., Iancu-Rubin, C., & Mascarenhas, J. (2021). PD-1 inhibition in advanced myeloproliferative neoplasms. Blood advances, 5(23), 5086–5097.

Saxena, M., van der Burg, S. H., Melief, C. J. M., & Bhardwaj, N. (2021). Therapeutic cancer vaccines. Nature reviews. Cancer, 21(6), 360–378.

Bhardwaj, N., Friedlander, P. A., Pavlick, A. C., Ernstoff, M. S., Gastman, B. R., Hanks, B. A., Curti, B. D., Albertini, M. R., Luke, J. J., Blazquez, A. B., Balan, S., Bedognetti, D., Beechem, J. M., Crocker, A. S., D'Amico, L., Danaher, P., Davis, T. A., Hawthorne, T., Hess, B. W., Keler, T., … Fling, S. P. (2020). Flt3 ligand augments immune responses to anti-DEC-205-NY-ESO-1 vaccine through expansion of dendritic cell subsets. Nature cancer, 1(12), 1204–1217.

Roudko, V., Bozkus, C. C., Orfanelli, T., McClain, C. B., Carr, C., O'Donnell, T., Chakraborty, L., Samstein, R., Huang, K. L., Blank, S. V., Greenbaum, B., & Bhardwaj, N. (2020). Shared Immunogenic Poly-Epitope Frameshift Mutations in Microsatellite Unstable Tumors. Cell, 183(6), 1634–1649.e17. https://doi.org/10.1016/j.cell.2020.11.004

Cimen Bozkus, C., Roudko, V., Finnigan, J. P., Mascarenhas, J., Hoffman, R., Iancu-Rubin, C., & Bhardwaj, N. (2019). Immune Checkpoint Blockade Enhances Shared Neoantigen-Induced T-cell Immunity Directed against Mutated Calreticulin in Myeloproliferative Neoplasms. Cancer discovery, 9(9), 1192–1207.

Saxena, M., Sabado, R. L., La Mar, M., Mohri, H., Salazar, A. M., Dong, H., Correa Da Rosa, J., Markowitz, M., Bhardwaj, N., & Miller, E. (2019). Poly-ICLC, a TLR3 Agonist, Induces Transient Innate Immune Responses in Patients With Treated HIV-Infection: A Randomized Double-Blinded Placebo Controlled Trial. Frontiers in immunology, 10, 725.

Saxena, M., Balan, S., Roudko, V., & Bhardwaj, N. (2018). Towards superior dendritic-cell vaccines for cancer therapy. Nature biomedical engineering, 2(6), 341–346.

Saxena, M., & Bhardwaj, N. (2018). Re-Emergence of Dendritic Cell Vaccines for Cancer Treatment. Trends in cancer, 4(2), 119–137.

Saxena, M., & Bhardwaj, N. (2017). Turbocharging vaccines: emerging adjuvants for dendritic cell based therapeutic cancer vaccines. Current opinion in immunology, 47, 35–43.